Sana Biotechnology Inc Files For Mixed Shelf; Size Not Disclosed
$SANA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- SEC Filing
- SEC Filing
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2025 | $5.00 | Outperform | Wedbush |
| 7/3/2025 | $12.00 | Overweight | Morgan Stanley |
| 3/18/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 3/14/2025 | $7.00 | Buy | Jefferies |
| 1/8/2025 | Hold → Buy | TD Cowen | |
| 11/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/26/2024 | $16.00 | Buy | Rodman & Renshaw |
| 1/16/2024 | $12.00 | Neutral → Buy | H.C. Wainwright |
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
SCHEDULE 13G - Sana Biotechnology, Inc. (0001770121) (Subject)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
Wedbush initiated coverage of Sana Biotechnology with a rating of Outperform and set a new price target of $5.00
Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00
Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference. About Sana BiotechnologySana Biotechnology, In
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen Technology Beyond T Cells to Second Cell Type, HSCs, Showing Potent and Specific in vivo Delivery Underscores Ability of Fusogen Technology to Deliver Diverse Payloads, including CRISPR Gene-Editing and Base-Editing Machinery Highlights Potential of Fusogen Platform in Diseases like Sickle Cell Disease and Beta Thalassemia Without the Need for Conditioning Chemotherapy Sana is Incorporating its Fusogen Technology to Develop SG293, a CD8-targeted Fusosome that Makes CD19-directed CA
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM
First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger. Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co
Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating